Sugi Predict

Sugi Predict / Targets / KLK2

KLK2

Kallikrein-2 · P20151 · KLK2 on Sugi Atlas →

906 patent compounds predicted against KLK2, 521 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9971041 SCHEMBL9971041 0.66 3/20
SCHEMBL3394756 SCHEMBL3394756 0.63 3/20
SCHEMBL5881673 SCHEMBL5881673 0.63 3/20
SCHEMBL2246988 SCHEMBL2246988 0.59 3/20
SCHEMBL1436662 SCHEMBL1436662 0.55 3/20
SCHEMBL9970972 SCHEMBL9970972 0.55 3/20
SCHEMBL8584551 SCHEMBL8584551 0.55 3/20
SCHEMBL16152335 SCHEMBL16152335 0.55 3/20
SCHEMBL10400079 SCHEMBL10400079 0.50 3/20
SCHEMBL7300801 SCHEMBL7300801 0.47 3/20
SCHEMBL7300806 SCHEMBL7300806 0.47 3/20
SCHEMBL2249449 SCHEMBL2249449 0.41 3/20
SCHEMBL22807612 SCHEMBL22807612 0.82 2/20
SCHEMBL12354626 SCHEMBL12354626 0.81 2/20
SCHEMBL7403534 SCHEMBL7403534 0.78 2/20
SCHEMBL2249441 SCHEMBL2249441 0.76 2/20
SCHEMBL4295336 SCHEMBL4295336 0.73 2/20
SCHEMBL4297455 SCHEMBL4297455 0.73 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7390446) 0.71 2/20
SCHEMBL17126273 SCHEMBL17126273 0.71 2/20

Clinical trials — most relevant to KLK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein PHASE4UNKNOWN
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism PHASE4COMPLETED
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer PHASE2COMPLETED
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer PHASE2WITHDRAWN
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA PHASE1/PHASE2RECRUITING
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer PHASE2COMPLETED
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma PHASE2COMPLETED
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery PHASE1/PHASE2COMPLETED
Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy PHASE2COMPLETED
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance PHASE2COMPLETED
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer PHASE1/PHASE2COMPLETED
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. PHASE2WITHDRAWN
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy PHASE2COMPLETED
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 PHASE1COMPLETED
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME PHASE1COMPLETED
Study to Assess PK, Safety and Tolerability in Healthy Subjects PHASE1COMPLETED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. PHASE1COMPLETED
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer PHASE1COMPLETED
Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer PHASE1COMPLETED
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population nanRECRUITING
Urinary Kallikrein and Hypertension: A Prospective Study nanCOMPLETED
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) nanRECRUITING
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia nanCOMPLETED
Prostasomes as Diagnostic Tool for Prostate Cancer Detection nanSUSPENDED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
Salivary Cytokines as Biomarker for Oral Health nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KLK2 binder may also engage these)

ProteinNameSimilarity
KLK3 Prostate-specific antigen 1.000 landscape →
P33619 — 0.999 P33619 →
Q07276 — 0.993 Q07276 →
P09582 — 0.993 P09582 →
Q6DT45 — 0.992 Q6DT45 →
Q28773 — 0.992 Q28773 →
KLK1 Kallikrein-1 0.990 landscape →
P56435 — 0.986 P56435 →
KLK13 Kallikrein-13 0.986 landscape →
Q76B45 — 0.985 Q76B45 →
KLK6 Kallikrein-6 0.985 landscape →
P50342 — 0.985 P50342 →
KLK7 Kallikrein-7 0.984 landscape →
P79204 — 0.984 P79204 →
P21842 — 0.983 P21842 →
P50341 — 0.983 P50341 →
TPSAB1 Tryptase beta-1 0.983 landscape →
P36369 — 0.982 P36369 →
P09650 — 0.982 P09650 →
Q9XSM2 — 0.982 Q9XSM2 →
P36373 — 0.981 P36373 →
TPSB2 Tryptase beta-2 0.981 landscape →
P21845 — 0.981 P21845 →
A7WPL7 — 0.981 A7WPL7 →
CMA1 Chymase 0.980 landscape →
P97592 — 0.980 P97592 →
P52195 — 0.980 P52195 →
Q9N2D1 — 0.980 Q9N2D1 →
P27435 — 0.980 P27435 →
P36368 — 0.979 P36368 →